Gene therapy by anti-tgf-b agents
CA 2213198 C · Owner: Border, Wayne A. · Inventors: Border, Wayne A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides methods for reducing a pathology in a subject characterized by a deleterious accumulation of TGF- .beta.-induced extracellular matrix in a tissue by introducing a nucleic acid encoding a TGF .beta.-specific inhibitory agent or active fragment thereof into a cell in the subject. In one embodiment the nucleic acid , encoding the TGF-.beta.-specific inhibitory agent is introduced into a cell in vivo by injection, for example in skeletal muscle. In another , embodiment the nucleic acid encoding the TGF .beta.-specific inhibitory agent is transfected into a cell ex vivo to obtain a cell expressing the agent, and the cell is then administered into the subject to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 14, 1996 and granted December 3, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 14, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 14, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.